Ideaya stock slashed af­ter GSK punts an op­tion

Af­ter two years, GSK is out on a part­nered pro­gram with Ideaya Bio­sciences — and in­vestors are not pleased.

The syn­thet­ic lethal­i­ty-fo­cused on­col­o­gy play­er re­port­ed ear­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER